CN106074573A - 复方酮康唑霜 - Google Patents
复方酮康唑霜 Download PDFInfo
- Publication number
- CN106074573A CN106074573A CN201610726599.6A CN201610726599A CN106074573A CN 106074573 A CN106074573 A CN 106074573A CN 201610726599 A CN201610726599 A CN 201610726599A CN 106074573 A CN106074573 A CN 106074573A
- Authority
- CN
- China
- Prior art keywords
- parts
- frost
- skin
- tinea
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 title claims abstract description 24
- 229960004125 ketoconazole Drugs 0.000 title claims abstract description 24
- 229960004703 clobetasol propionate Drugs 0.000 title claims abstract description 8
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 title claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 15
- 239000010703 silicon Substances 0.000 claims abstract description 15
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims abstract description 13
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims abstract description 13
- 229940097572 chloromycetin Drugs 0.000 claims abstract description 13
- 229960000785 fluocinonide Drugs 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 10
- 229960003291 chlorphenamine Drugs 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 29
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 4
- WRWRKDRWMURIBI-UHFFFAOYSA-M mercuric amidochloride Chemical compound N[Hg]Cl WRWRKDRWMURIBI-UHFFFAOYSA-M 0.000 claims description 3
- 229960000432 mercuric amidochloride Drugs 0.000 claims description 3
- 229960002523 mercuric chloride Drugs 0.000 claims description 3
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 206010000496 acne Diseases 0.000 abstract description 19
- 210000003491 skin Anatomy 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 16
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 11
- 208000002474 Tinea Diseases 0.000 abstract description 9
- 208000003351 Melanosis Diseases 0.000 abstract description 7
- 241000233866 Fungi Species 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 210000000170 cell membrane Anatomy 0.000 abstract description 5
- 230000002538 fungal effect Effects 0.000 abstract description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 abstract description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 abstract description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 abstract description 4
- 206010005913 Body tinea Diseases 0.000 abstract description 4
- 201000004624 Dermatitis Diseases 0.000 abstract description 4
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 abstract description 4
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 4
- 201000004681 Psoriasis Diseases 0.000 abstract description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract description 4
- 206010067197 Tinea manuum Diseases 0.000 abstract description 4
- 208000010668 atopic eczema Diseases 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 abstract description 4
- 230000019612 pigmentation Effects 0.000 abstract description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract description 4
- 201000003875 tinea corporis Diseases 0.000 abstract description 4
- 201000004647 tinea pedis Diseases 0.000 abstract description 4
- 208000009043 Chemical Burns Diseases 0.000 abstract description 3
- 208000018380 Chemical injury Diseases 0.000 abstract description 3
- 206010008570 Chloasma Diseases 0.000 abstract description 3
- 201000010618 Tinea cruris Diseases 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 210000002615 epidermis Anatomy 0.000 abstract description 3
- 231100000017 mucous membrane irritation Toxicity 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 206010012504 Dermatophytosis Diseases 0.000 description 3
- 241001460074 Microsporum distortum Species 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- -1 imidazoles dioxane derivative Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开一种复方酮康唑霜。由下述重量份的原料制成：酮康唑15‑30份；肤轻松2‑5份；氯霉素40‑60份；扑尔敏40‑60份；冰片200‑400份；二甲亚砜40‑60份；乙醇100‑200份；甘油100‑200份；硅霜800‑1200份。本发明通过合理调配上述原料药，涂抹皮肤后从皮肤表皮层进入真皮层，从而抑制真菌细胞膜麦角固醇的生物合成而抑制真菌生长。能有效的祛除皮肤痤疮、青春痘、改善黄褐斑、雀斑、物理机化学烧伤引起的色素沉着等问题，对手癣、足癣、体癣、股癣银屑病、湿疹、脂溢性皮炎、粉刺、青春痘、暗疮等均有疗效且成本低廉、制作简单、使用方便。试验及真菌检查结果表明本发明在使用中未发现有毒副作用及不良反应，无皮肤、粘膜刺激性，值得临床应用推广。
Description
技术领域
本发明属于化学制药技术领域，具体涉及一种治疗浅部真菌感染的外用药－复方酮康唑霜。
背景技术
浅部真菌感染指限于皮肤最外层(表皮)、甲板、毛发和粘膜的真菌感染，其主要病原菌为皮肤癣菌、马拉色菌、念珠菌等。此类疾病是皮肤科最常见的感染性疾病，据统计其发病率可占全部皮肤病的1/4左右。
酮康唑是1976年人工合成的咪唑类二恶烷衍生物。作用于真菌细胞膜形成过程中的羊毛类固醇14α-去甲基化酶，抑制羊毛类固醇向14α-去甲基羊毛类固醇的转化，从而抑制真菌细胞膜麦角固醇的生物合成而抑制真菌生长。酮康唑具有广谱抗真菌作用，尤其对皮肤癣菌、念珠菌和马拉色菌具有明显的抑制作用。
发明内容
为达到上述目的，本发明提供一种治疗浅部真菌感染的外用药复方酮康唑霜。
为达到上述目的，本发明的复方酮康唑霜，由下述重量份的原料制成：
酮康唑15-30份肤轻松2-5份氯霉素40-60份扑尔敏40-60份冰片200-400份
二甲亚砜40-60份乙醇100-200份甘油100-200份硅霜800-1200份；
其制备方法为：取上述的酮康唑、肤轻松和扑尔敏用二甲亚砜溶解得组合物1；取上述的氯霉素、冰片用乙醇溶解后与甘油混匀得组合物2；将组合物1和组合物2混匀后加到硅霜中搅拌均匀。
较佳的，所述的制备方法还包括在所述的硅霜中加入下述重量份的原料的步骤：3％双氧水20份、0.5-1％升汞酒精20份、2-3％氢醌霜10份和/或5％白降汞10份。
本发明通过合理调配上述原料药，涂抹皮肤后从皮肤表皮层进入真皮层，从而抑制真菌细胞膜麦角固醇的生物合成而抑制真菌生长。通过梳理吸收、消炎散瘀、祛除痘印、改善粗暗黄皮肤有特效功能，能有效的祛除皮肤痤疮、青春痘、改善黄褐斑、雀斑、物理机化学烧伤引起的色素沉着等问题，对手癣、足癣、体癣、股癣银屑病、湿疹、脂溢性皮炎、粉刺、青春痘、暗疮等均有疗效且成本低廉、制作简单、使用方便。试验及真菌检查结果表明本发明在使用中未发现有毒副作用及不良反应，无皮肤、粘膜刺激性，值得临床应用推广。
具体实施方式
下面结合实施例对本发明作进一步的说明。
本发明的复方酮康唑霜，由下述重量份的原料制成：
酮康唑15-30份肤轻松2-5份氯霉素40-60份扑尔敏40-60份冰片200-400份
二甲亚砜40-60份乙醇100-200份甘油100-200份硅霜800-1200份；
其制备方法为：取上述的酮康唑、肤轻松和扑尔敏用二甲亚砜溶解得组合物1；取上述的氯霉素、冰片用乙醇溶解后与甘油混匀得组合物2；将组合物1和组合物2混匀后加到硅霜中搅拌均匀。
上述的本发明为外用药，使用时，取少许涂抹于患处，药物经皮肤表皮层进入真皮层，从而抑制真菌细胞膜麦角固醇的生物合成而抑制真菌生长。通能有效的祛除皮肤痤疮、青春痘、改善黄褐斑、雀斑、物理机化学烧伤引起的色素沉着等问题，对手癣、足癣、体癣、股癣银屑病、湿疹、脂溢性皮炎、粉刺、青春痘、暗疮等均有疗效且成本低廉、制作简单、使用方便。
实施例1
酮康唑15份肤轻松2份氯霉素40份扑尔敏50份冰片200份
二甲亚砜40份乙醇100份甘油200份硅霜800份；
其制备方法为：取上述的酮康唑、肤轻松和扑尔敏用二甲亚砜溶解得组合物1；取上述的氯霉素、冰片用乙醇溶解后与甘油混匀得组合物2；将组合物1和组合物2和0.5-1％升汞酒精20份混匀后加到硅霜中搅拌均匀。
实施例2
酮康唑20份肤轻松3份氯霉素55份扑尔敏50份冰片300份
二甲亚砜50份乙醇150份甘油150份硅霜1000份；
其制备方法为：取上述的酮康唑、肤轻松和扑尔敏用二甲亚砜溶解得组合物1；取上述的氯霉素、冰片用乙醇溶解后与甘油混匀得组合物2；将组合物1、组合物2、2-3％氢醌霜10份和5％白降汞10份混匀后加到硅霜中搅拌均匀。
实施例3
酮康唑20份肤轻松5份氯霉素40份扑尔敏40份冰片400份
二甲亚砜60份乙醇200份甘油100份硅霜1100份；
其制备方法为：取上述的酮康唑、肤轻松和扑尔敏用二甲亚砜溶解得组合物1；取上述的氯霉素、冰片用乙醇溶解后与甘油混匀得组合物2；将组合物1和组合物2混匀后加到硅霜中搅拌均匀。使用时，涂于患处即可。
经过临床数百例的治疗证明，本发明能有效的祛除皮肤痤疮、青春痘，改善黄褐斑、雀斑、物理机化学烧伤引起的色素沉着等问题，对手癣、足癣、体癣、股癣银屑病、湿疹、脂溢性皮炎、粉刺、青春痘、暗疮等均有疗效。从2014年至2016年的两年中应用本方剂，在门诊随机治疗各种上述病症400余例。单纯小面积皮肤癣病，一般在72小时左右即可达到临床基本治愈。严重的皮肤癣病，一般在三个月内完全可治愈。现举例如下：
病例1
孙XX，女，33岁，怀孕期间开始面部出现色斑，面积较大，在其它医院治疗过无显效，后来我院治疗，诊为孕后激素原因造成面部色斑，用本药治疗，一个月后见效，色斑大面消失，又巩固用药2个月，现已痊愈。
病例2
周X，女，20岁，沈阳市和平区6马路9号，患面部色斑，试用过许多祛斑药，均无疗效，后来我院用中药治疗，用本药20余天开始有效，后又继续用药两个月现已痊愈。
病例3
刘XX，男，20岁，患面部粉刺(痤疮)已两年，多处医治无显效，后来我院用本药治疗，用药十天有效，感染消失，后又用药一个月已痊愈。
病例4
张XX，男，52岁，患面部粉刺多年，喝酒更加重，时而合并感染形成毛囊炎。在医大皮肤科多次治疗无显效，后来我院治疗，经用上述药物后半月见效，现面部已无大面粉刺，又用一个月药已痊愈。
以上所述仅为本发明的优选实施例而已，并不用于限制本发明，对于本领域的技术人员来说，本发明可以有各种更改和变化。凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (2)
1.一种复方酮康唑霜，其特征在于，由下述重量份的原料制成：
酮康唑15-30份肤轻松2-5份氯霉素40-60份扑尔敏40-60份冰片200-400份
二甲亚砜40-60份乙醇100-200份甘油100-200份硅霜800-1200份；
其制备方法为：取上述配方量的酮康唑、肤轻松和扑尔敏用二甲亚砜溶解得组合物1；取上述的氯霉素、冰片用乙醇溶解后与甘油混匀得组合物2；将组合物1和组合物2混匀后加到硅霜中搅拌均匀。
2.如权利要求1所述的复方酮康唑霜，其特征在于，所述的制备方法还包括在所述的硅霜中加入下述重量份的原料的步骤：
3％双氧水20份、0.5-1％升汞酒精20份、2-3％氢醌霜10份和/或5％白降汞10份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610726599.6A CN106074573A (zh) | 2016-08-26 | 2016-08-26 | 复方酮康唑霜 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610726599.6A CN106074573A (zh) | 2016-08-26 | 2016-08-26 | 复方酮康唑霜 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106074573A true CN106074573A (zh) | 2016-11-09 |
Family
ID=57225205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610726599.6A Pending CN106074573A (zh) | 2016-08-26 | 2016-08-26 | 复方酮康唑霜 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074573A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004093870A1 (en) * | 2003-03-20 | 2004-11-04 | Pharmacia Corporation | Treatment and prevention of otic disorders |
| CN104127422A (zh) * | 2014-07-17 | 2014-11-05 | 李泽填 | 一种治疗瘙痒和青春痘的组合物及其制备方法 |
-
2016
- 2016-08-26 CN CN201610726599.6A patent/CN106074573A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004093870A1 (en) * | 2003-03-20 | 2004-11-04 | Pharmacia Corporation | Treatment and prevention of otic disorders |
| CN104127422A (zh) * | 2014-07-17 | 2014-11-05 | 李泽填 | 一种治疗瘙痒和青春痘的组合物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 潘友金等: ""局部外用药物治疗脓包痤疮50例疗效观察"", 《现代中西医结合杂志》 * |
| 王顺年: "《临床合理用药指南》", 31 July 2015, 人民军医出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101135147B1 (ko) | 5-아미노레불린산을 함유한 여드름 치료용 화장료 조성물 | |
| CN102379879B (zh) | 一种含有利拉萘酯和糠酸莫米松的局部应用复方药物组合物 | |
| CN103127140B (zh) | 一种治疗银屑病的复方外用药物 | |
| CN100569254C (zh) | 治疗小儿湿疹的外用软膏 | |
| CN106074573A (zh) | 复方酮康唑霜 | |
| CN102048732B (zh) | 一种治疗真菌感染的外用药物组合物 | |
| CN1168448C (zh) | 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物 | |
| CN103908425B (zh) | 一种抗真菌用氟曲马唑软膏制剂及其制备工艺 | |
| CN104771405A (zh) | 一种复方特比萘芬制剂及其应用 | |
| WO2024011868A1 (zh) | 香兰基丁醚在制备治疗头屑和体癣产品中的应用 | |
| CN105326923A (zh) | 一种发酵鼻炎贴膏 | |
| CN103977110A (zh) | 一种治疗牛皮癣植物软膏及其制备方法 | |
| CN103520206B (zh) | 一种治疗皮肤病的外用药物组合物及其制备方法 | |
| CN104523711B (zh) | 酮康他索乳膏及其制备方法 | |
| CN105726564A (zh) | 一种治疗皮肤癣病的药膏 | |
| CN103142619B (zh) | 一种治疗皮炎的药物组合物及其制备方法 | |
| CN105395471A (zh) | 一种以硝酸益康唑为活性成分的皮肤病外用乳膏及制备方法 | |
| CN101422430B (zh) | 酮康唑麝香草酚治皮癣溶液 | |
| CN105101966A (zh) | 一种含埃克替尼的皮肤外用药物组合物及其应用 | |
| CN102920997B (zh) | 一种复方癣药膏 | |
| CN109381483A (zh) | 一种治疗皮肤病的药物 | |
| CN106880670A (zh) | 一种治疗疥疮的药物 | |
| CN106166180A (zh) | 一种治疗口腔溃疡的中药组合物及其应用 | |
| CN104997726A (zh) | 防治皮肤癣的外用乳膏 | |
| CN106668249A (zh) | 一种治疗皮肤感染和过敏的中西药复方外用药及其制作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |